All In Biotech

Drug Trial Radar · NCT06771115

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

Jan 7, 2025

Primary completion

Sep 10, 2025

Study completion Sep 10, 2025

Sponsor

Lead sponsor
Zomagen Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in combination with semaglutide, or placebo in combination with semaglutide. The study consisted of a 30-day screening period, a 12-week double-blind treatment period, and a 30-day follow-up period. The maximum treatment duration was 12 weeks.

Conditions

  • Obesity

Interventions

  • PlaceboDrug

    Placebo

  • VTX3232 30 mgDrug

    VTX3232 30 mg

  • Placebo in combination with semaglutideDrug

    Placebo in combination with semaglutide

  • VTX3232 30 mg in combination with semaglutideDrug

    VTX3232 30 mg in combination with semaglutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Any Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of study treatment to Week 16

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • 840005

    Birmingham, Alabama

  • 840003

    Lake Forest, California

  • 840011

    Long Beach, California

  • 840001

    Largo, Florida

  • 840012

    Ocoee, Florida

  • 840016

    Port Orange, Florida

  • 840014

    Newton, Kansas

  • 840015

    Marrero, Louisiana

  • 840017

    Marrero, Louisiana

  • 840002

    Austin, Texas

  • 840006

    Dallas, Texas

  • 840013

    San Antonio, Texas

  • 840018

    San Antonio, Texas

  • 840010

    Waco, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.